Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME) (MIVI-II)

This study has been completed.
Information provided by (Responsible Party):
ThromboGenics Identifier:
First received: December 14, 2006
Last updated: December 2, 2014
Last verified: April 2014
A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with DME.

Condition Intervention Phase
Diabetic Macular Edema
Drug: ocriplasmin
Other: Sham injection
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical Posterior Vitreous Detachment (PVD) Induction for Treatment of DME.

Resource links provided by NLM:

Further study details as provided by ThromboGenics:

Primary Outcome Measures:
  • PVD Induction [ Time Frame: Day 14 post-injection ] [ Designated as safety issue: No ]
    The primary efficacy variable was the proportion of patients with total posterior vitreous detachment (PVD) on Day 14 as determined by a masked central reading center (CRC) using 4-quadrant B-scan and optical coherence tomography (OCT)

Enrollment: 51
Study Start Date: December 2006
Study Completion Date: March 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ocriplasmin 25µg
25µg ocriplasmin intravitreal injection versus sham injection
Drug: ocriplasmin
Intravitreal injection, single administration
Other Name: microplasmin
Experimental: Ocriplasmin 75µg
75µg ocriplasmin intravitreal injection versus sham injection
Drug: ocriplasmin
Intravitreal injection, single administration
Other Name: microplasmin
Experimental: Ocriplasmin 125µg
125µg ocriplasmin intravitreal injection versus sham injection
Drug: ocriplasmin
Intravitreal injection, single administration
Other Name: microplasmin
Sham Comparator: sham injection
Sham injection
Other: Sham injection
Sham intravitreal injection


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria include:

  • patients >18 years of age with Diabetic Macular Edema

Exclusion Criteria include:

  • PVD present at baseline
  • Vitreous hemorrhage
  • Certain vitreoretinal conditions including proliferative disease, rhegmatogenous retinal detachment, and proliferative vitreoretinopathy (PVR)
  • Patients who have had a vitrectomy in the study eye at any time
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00412451

ZNA OCMW Antwerpen
Antwerpen, Belgium, 2020
University Hospital of Ghent
Ghent, Belgium, B-9000
University Hospital Leuven
Leuven, Belgium
Ludwig Maximillian University
Munich, Germany
University of Milan
Milan, Italy
Azienda Ospedaliero-Universitaria Pisana
Pisa, Italy
Institute of Ophtalmology, Policlinico A: Gemelli (University Hospital),Catholic University of Sacred Heart
Rome, Italy, 00168
Ospedale di Circolo di Varese, Insubria University
Varese, Italy, 21100
Academic Hospital Groningen
Groningen, Netherlands, 9700 RB
Het Oogziekenhuis Rotterdam
Rotterdam, Netherlands, 3011 BH
Institut de Microcirurgia Ocular de Barcelona
Barcelona, Spain, 08022
Hospital Vall D'Hebron
Barcelona, Spain, 08035
Instituto Technologico de Oftalmologia SL.
Santiago de Compostela, Spain
United Kingdom
Royal Liverpool & Broadgreen Hospital
Liverpool, United Kingdom, L7 8XP
Moorfields Eye Hospital
London, United Kingdom, EC1V 2PD
Sponsors and Collaborators
  More Information

Responsible Party: ThromboGenics Identifier: NCT00412451     History of Changes
Other Study ID Numbers: TG-MV-002 
Study First Received: December 14, 2006
Results First Received: July 4, 2013
Last Updated: December 2, 2014
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Belgium: Ministry of Social Affairs, Public Health and the Environment
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Spain: Ministry of Health

Keywords provided by ThromboGenics:
Diabetic Macular Edema
Diabetic Retinopathy

Additional relevant MeSH terms:
Macular Edema
Vitreous Detachment
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on December 08, 2016